Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. The company offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomodulator… Read more
Formosa Laboratories Inc (4746) - Total Assets
Latest total assets as of September 2025: NT$13.54 Billion TWD
Based on the latest financial reports, Formosa Laboratories Inc (4746) holds total assets worth NT$13.54 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Formosa Laboratories Inc - Total Assets Trend (2009–2024)
This chart illustrates how Formosa Laboratories Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Formosa Laboratories Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Formosa Laboratories Inc's total assets of NT$13.54 Billion consist of 42.2% current assets and 57.8% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 9.8% |
| Accounts Receivable | NT$1.26 Billion | 9.0% |
| Inventory | NT$1.71 Billion | 12.3% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$154.64 Million | 1.1% |
| Goodwill | NT$60.40 Million | 0.4% |
Asset Composition Trend (2009–2024)
This chart illustrates how Formosa Laboratories Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Formosa Laboratories Inc's current assets represent 42.2% of total assets in 2024, an increase from 0.0% in 2009.
- Cash Position: Cash and equivalents constituted 9.8% of total assets in 2024, up from 5.0% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 12.3% of total assets.
Formosa Laboratories Inc Competitors by Total Assets
Key competitors of Formosa Laboratories Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF
|
USA | $67.26 Billion |
|
Kamada
NASDAQ:KMDA
|
USA | $378.79 Million |
|
One World Pharma Inc
OTCQB:OWPC
|
USA | $6.62 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩654.63 Billion |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078
|
China | CN¥27.28 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥4.97 Billion |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM363.90 Million |
Formosa Laboratories Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Formosa Laboratories Inc generates 0.34x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Formosa Laboratories Inc generates $ 1.13 in net profit.
Formosa Laboratories Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.86 | 2.13 | 1.04 |
| Quick Ratio | 1.23 | 1.41 | 0.56 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$2.43 Billion | NT$ 2.96 Billion | NT$ 108.26 Million |
Formosa Laboratories Inc - Advanced Valuation Insights
This section examines the relationship between Formosa Laboratories Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 1.9% |
| Total Assets | NT$13.90 Billion |
| Market Capitalization | $160.16 Million USD |
Valuation Analysis
Below Book Valuation: The market values Formosa Laboratories Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Formosa Laboratories Inc's assets grew by 1.9% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Formosa Laboratories Inc (2009–2024)
The table below shows the annual total assets of Formosa Laboratories Inc from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$13.90 Billion | +1.90% |
| 2023-12-31 | NT$13.64 Billion | +6.94% |
| 2022-12-31 | NT$12.75 Billion | +6.11% |
| 2021-12-31 | NT$12.02 Billion | +16.83% |
| 2020-12-31 | NT$10.29 Billion | +7.05% |
| 2019-12-31 | NT$9.61 Billion | +10.12% |
| 2018-12-31 | NT$8.73 Billion | +20.49% |
| 2017-12-31 | NT$7.24 Billion | +7.53% |
| 2016-12-31 | NT$6.73 Billion | +4.31% |
| 2015-12-31 | NT$6.46 Billion | +13.46% |
| 2014-12-31 | NT$5.69 Billion | +14.01% |
| 2013-12-31 | NT$4.99 Billion | +23.67% |
| 2012-12-31 | NT$4.04 Billion | +29.62% |
| 2011-12-31 | NT$3.11 Billion | +31.08% |
| 2010-12-31 | NT$2.38 Billion | +40.36% |
| 2009-12-31 | NT$1.69 Billion | -- |